Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (SFB1066/Q3)
Text and Data Mining valid from 2018-08-15
Received: 6 April 2018
Accepted: 7 August 2018
First Online: 15 August 2018
Ethics approval and consent to participate
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Ethical approval was given by the Ethik Kommission Rheinland-Pfalz (837.548.13 (9233-A)). Informed consent was obtained from all individual participants included in the study.All animal experiments were performed in accordance with the federal guidelines and approved by the Regional Investigational Authority (Landesuntersuchungsamt; permission no. 23177-07/G12-1-092).
: Consent for publication was obtained.
: US and MD are inventors on patents and patent applications covering therapeutic RNA vaccine technologies described in this article. CL declares the following competing interests: Advisory board for Roche, BMS, Novartis, Amgen, Leo, Pierre Fabre, and MSD. Speakers fee from Roche, BMS, Novartis, Amgen, Pierre Fabre, MSD, and Roche-Posay. Travel reimbursement from Roche, BMS, Novartis, Amgen, and Pierre Fabre. The other authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.